Pipeline Overview

Tarveda’s pipeline exemplifies the company’s Pentarin™ platform that creates novel treatments designed to improve the effectiveness of cancer therapies for solid tumors.

Tarveda’s lead Pentarin clinical drug candidate, PEN‑221, targets the somatostatin receptor 2 (SSTR2) for treatment of patients with tumors including neuroendocrine, small cell lung and other cancers that express SSTR2. PEN-221 comprises a peptide, which is highly selective for SSTR2 conjugated to the potent cytotoxic DM1 through a tuned cleavable linker. PEN-221 is in a Phase 1/2a clinical trial.

Tarveda is also advancing its HSP90 drug conjugate platform with lead drug candidate PEN‑866, which is miniature drug conjugate that selectively binds to the intracellular target, Heat Shock Protein 90 (HSP90), and is linked to the payload SN-38. PEN-866, is designed to treat patients with solid tumors including those with colorectal, small cell lung, and pancreatic cancers and sarcoma. 

Tarveda is advancing our pipeline with a focus on both cell surface and intracellular targets in solid tumors and has generated data demonstrating that Pentarins will be effective as a new and innovative class of drug conjugates with ability to effectively penetrate into tumor tissue.